Cognoptix to focus on early Alzheimer's diagnosis at the point of care

April 8, 2014

At the 9th Annual Lux Executive Summit: Seizing the Innovation Initiative event held on March 31, 2014, Cognoptix president and CEO Paul Hartung told a group of analysts that the company's “...vision is to change the course of Alzheimer’s disease by enabling early diagnosis at the point of care.”

At the 9th Annual Lux Executive Summit: Seizing the Innovation Initiative (Boston, MA) event held on March 31, 2014, Cognoptix (Acton, MA) president and CEO Paul Hartung told a group of analysts that the company's “...vision is to change the course of Alzheimer’s disease by enabling early diagnosis at the point of care.”

To that end, the company published strong results from a multisite clinical trial of its SAPPHIRE II eye test, which identifies Alzheimer’s disease patients via a beta-amyloid (Ab) signature in their eyes, in the peer-reviewed Journal of Alzheimer’s Disease & Other Dementias (AJA) in February 2014.

“We have made great progress, ” Hartung added, “in developing an early-stage, noninvasive diagnostic test for AD designed to allow treatment to start before significant neuronal loss and irreversible brain damage occur.”

Hartung has closed Seed, Series A, Series B, and Series C financing rounds for the company, totaling $17 million with an international Angel and VC syndicate.

For more information, please visit http://dx.doi.org/10.1177/1533317513520214.

-----

Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn

Subscribe now to BioOptics World magazine; it's free!